| pubmed-article:10362148 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C0597298 | lld:lifeskim |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C1334510 | lld:lifeskim |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C0385723 | lld:lifeskim |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C1537474 | lld:lifeskim |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C1441547 | lld:lifeskim |
| pubmed-article:10362148 | lifeskim:mentions | umls-concept:C0439064 | lld:lifeskim |
| pubmed-article:10362148 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10362148 | pubmed:dateCreated | 1999-6-24 | lld:pubmed |
| pubmed-article:10362148 | pubmed:abstractText | Peptides derived from the melanoma-associated MART-1/Melan-A antigen are currently implemented in immunotherapy for inducing or augmenting T-cell responses directed against peptides expressed by autologous tumor cells in HLA-A2+ patients with melanoma. Here, we describe the specificity of the T-cell clone SK29-FFM1.1, which secretes GM-CSF in response to a panel of synthetic MART-1/Melan-A-derived peptides, including the naturally presented ILTVILGVL(32-40), but exhibits cytotoxicity and IFN-gamma secretion exclusively to the MART-1/Melan-A derived peptide AAGIGILTV(27-35). In addition, cytotoxic T-lymphocyte (CTL) clone SK29-FFM1.1 recognizes 3 different naturally processed and presented peptides on HLA-A2+ MART-1/Melan-A+ melanoma cells, as defined by cytotoxicity and IFN-gamma and GM-CSF secretion. Processing and presentation of MART-1/Melan-A peptides appears to be different in cells of non-melanocytic origin, as shown by the characterization of naturally presented peptides displayed by HLA-A2+ colorectal cancer cells transduced with a MART-1/Melan-A gene-containing retrovirus. Our data suggest that multiple epitopes, including ILTVILGVL and different isoforms of AAGIGILTV derived from MART-1/Melan-A may be naturally presented by melanoma cells to the immune system. | lld:pubmed |
| pubmed-article:10362148 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10362148 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10362148 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10362148 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:10362148 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:KnuthAA | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:JägerEE | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:CastelliCC | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:HöhnHH | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:MomburgFF | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:MaeurerM JMJ | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:SeligerBB | lld:pubmed |
| pubmed-article:10362148 | pubmed:author | pubmed-author:KarbadeVV | lld:pubmed |
| pubmed-article:10362148 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10362148 | pubmed:day | 11 | lld:pubmed |
| pubmed-article:10362148 | pubmed:volume | 81 | lld:pubmed |
| pubmed-article:10362148 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10362148 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10362148 | pubmed:pagination | 979-84 | lld:pubmed |
| pubmed-article:10362148 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:meshHeading | pubmed-meshheading:10362148... | lld:pubmed |
| pubmed-article:10362148 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10362148 | pubmed:articleTitle | Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. | lld:pubmed |
| pubmed-article:10362148 | pubmed:affiliation | Medizinische Klinik II, Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany. | lld:pubmed |
| pubmed-article:10362148 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10362148 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10362148 | lld:pubmed |
